HRP20250664T1 - Liječenje zatajenja srca i srčane ishemijske reperfuzijske ozljede - Google Patents

Liječenje zatajenja srca i srčane ishemijske reperfuzijske ozljede

Info

Publication number
HRP20250664T1
HRP20250664T1 HRP20250664TT HRP20250664T HRP20250664T1 HR P20250664 T1 HRP20250664 T1 HR P20250664T1 HR P20250664T T HRP20250664T T HR P20250664TT HR P20250664 T HRP20250664 T HR P20250664T HR P20250664 T1 HRP20250664 T1 HR P20250664T1
Authority
HR
Croatia
Prior art keywords
inhibitor
shock wave
dpp
use according
composition
Prior art date
Application number
HRP20250664TT
Other languages
English (en)
Croatian (hr)
Inventor
Salomon Narodden
Original Assignee
Salomon Narodden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salomon Narodden filed Critical Salomon Narodden
Publication of HRP20250664T1 publication Critical patent/HRP20250664T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813Exopeptidases (3.4.11. to 3.4.19)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/22Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/225Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005Dipeptidyl-peptidase IV (3.4.14.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20250664TT 2016-11-24 2017-11-17 Liječenje zatajenja srca i srčane ishemijske reperfuzijske ozljede HRP20250664T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1619861.6A GB201619861D0 (en) 2016-11-24 2016-11-24 Treatments for heart failure and cardiac ischaemic reperfusion injury
EP17817018.9A EP3544624B1 (en) 2016-11-24 2017-11-17 Treatments for heart failure and cardiac ischaemic reperfusion injury
PCT/GB2017/053473 WO2018096319A1 (en) 2016-11-24 2017-11-17 Treatments for heart failure and cardiac ischaemic reperfusion injury

Publications (1)

Publication Number Publication Date
HRP20250664T1 true HRP20250664T1 (hr) 2025-10-24

Family

ID=58073526

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20250664TT HRP20250664T1 (hr) 2016-11-24 2017-11-17 Liječenje zatajenja srca i srčane ishemijske reperfuzijske ozljede

Country Status (16)

Country Link
US (1) US20190374623A1 (https=)
EP (1) EP3544624B1 (https=)
JP (1) JP7231543B2 (https=)
KR (1) KR102678011B1 (https=)
CN (1) CN109996558A (https=)
AU (1) AU2017365926B2 (https=)
CA (1) CA3044624A1 (https=)
ES (1) ES3017482T3 (https=)
GB (1) GB201619861D0 (https=)
HR (1) HRP20250664T1 (https=)
HU (1) HUE071244T2 (https=)
MY (1) MY200960A (https=)
PL (1) PL3544624T3 (https=)
RS (1) RS66778B9 (https=)
RU (1) RU2767445C2 (https=)
WO (1) WO2018096319A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023281447A1 (en) * 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event
US20240122794A1 (en) * 2022-10-12 2024-04-18 Softwave Tissue Regeneration Technologies, Inc. Acoustic shock wave or pressure pulse treatment and methods of use for anti-aging
CN115998768B (zh) * 2023-02-07 2024-01-30 西南医科大学 M2型巨噬细胞外泌体在制备治疗心肌缺血再灌注损伤药物中的应用
CN117257785A (zh) * 2023-11-09 2023-12-22 新疆医科大学 没食子酸及其衍生物在制备预防和/或治疗心肌损伤药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2007416T3 (pl) * 2006-04-19 2018-05-30 Ludwig-Maximilians-Universität München Parathormon (PTH) do zastosowania w leczeniu niedokrwienia
US8455435B2 (en) * 2006-04-19 2013-06-04 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia
MX2011009852A (es) * 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
EP3110449B1 (en) * 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor

Also Published As

Publication number Publication date
GB201619861D0 (en) 2017-01-11
RS66778B1 (sr) 2025-06-30
WO2018096319A1 (en) 2018-05-31
RU2767445C2 (ru) 2022-03-17
RU2019119110A3 (https=) 2021-08-30
JP2020510616A (ja) 2020-04-09
PL3544624T4 (pl) 2025-11-03
JP7231543B2 (ja) 2023-03-01
MY200960A (en) 2024-01-26
HUE071244T2 (hu) 2025-07-28
EP3544624C0 (en) 2025-02-12
RU2019119110A (ru) 2020-12-24
KR20190100199A (ko) 2019-08-28
PL3544624T3 (pl) 2025-11-03
US20190374623A1 (en) 2019-12-12
KR102678011B1 (ko) 2024-06-25
EP3544624B1 (en) 2025-02-12
AU2017365926A1 (en) 2019-07-04
CA3044624A1 (en) 2018-05-31
ES3017482T3 (en) 2025-05-13
EP3544624A1 (en) 2019-10-02
AU2017365926B2 (en) 2025-06-05
RS66778B9 (sr) 2025-08-29
CN109996558A (zh) 2019-07-09

Similar Documents

Publication Publication Date Title
HRP20250664T1 (hr) Liječenje zatajenja srca i srčane ishemijske reperfuzijske ozljede
Mehta et al. Contemporary acupressure therapy: Adroit cure for painless recovery of therapeutic ailments
Cassar et al. Safety and efficacy of extracorporeal shock wave myocardial revascularization therapy for refractory angina pectoris
JP2020033360A5 (https=)
AR077484A1 (es) Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion
CR9181A (es) Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa
Solari et al. Pituitary adenomas: what are the key features? What are the current treatments? Where is the future taking us?
JP2020510616A5 (https=)
WO2015070050A8 (en) Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
WO2004112565A3 (en) Diagnosis and treatment of liver, pulmonary and cardiac fibrosis
Loghmani et al. Instrument-assisted soft tissue mobilization in healthy young adult males mobilizes tissue-resident mesenchymal stem cells into circulation
Zagorulko et al. Integrative methods of diagnosis and treatment of the chronical pain
RU2010114571A (ru) Применение g-csf для лечения инсульта
Inci et al. Ventricular fibrillation development following atrial fibrillation after the ingestion of sildenaphil in a patient with Wolff-Parkinson-White syndrome
UA54736U (uk) Спосіб лікування пацієнтів з еректильною дисфункціею
Dufourni et al. Left ventricular function during atrial fibrillation and follow up after succesfull cardioversion to sinus rhythm in warmblood horses
Dulsat European Society of Cardiology (ESC) Congress 2019. Paris, France-August 31-September 4, 2019
Jung Benefits from the Early Initiation of Macitentan for Pulmonary Arterial Hypertension
RU2016107521A (ru) Способ лечения задержки психоречевого развития и двигательных нарушений при нервно-психических заболеваниях больных
Tada Escitalopram/lansoprazole interaction
Lin et al. Improvement of exercise performance and attenuation of a marker of muscle damage by Epimedium Brevicornum supplementation in mice
Xu Interferon-β-1b
Khaled et al. Clinical results of the cellwave study using novel extracorporeal shock wave application for enhancing the efficacy of cell therapy
RU2010116983A (ru) Способ лечения больных хронической сердечной недостаточностью ишемического генеза
CN106540081A (zh) 一种治风心病引起的心衰的配方